title: GE132+Natural: Novel promising dietetic supplement with antiproliferative influence on prostate, colon, and breast cancer cells.
abstract: OBJECTIVE
  Natural products have been investigated for promising new leads in pharmaceutical development. The purpose of this study was to analyze the biological effect of GE132+Natural, a novel supplement consisting of 5 compounds: Resveratrol, Ganoderma lucidum, Sulforaphane, Lycopene and Royal jelly.
  
  
  METHODS
  The antiproliferative activity of GE132+Natural was tested on 3 different human cancer cell lines: MCF7 (breast cancer cells), PC3 (prostate cancer cells), and SW480 (colon cancer cells), as well as on EA.hy 926 (normal human endothelial cell line). In addition, the cytotoxicity of GE132+- Natural on the proliferation of primary human mesenchymal stem cells isolated from dental pulp (DP=MSC), along with its in vitro impact on different peripheral blood parameters, was determined.
  
  
  RESULTS
  The results revealed high antiproliferative activity of GE132+Natural on all tested cancer cell lines (PC3, MCF7 and SW480), as well as on the EA.hy 926 endothelial cell line in a dose-dependent manner. However, applied in a wide range of concentrations GE132+Natural did not affect both the proliferation of primary mesenchymal stem cells and the peripheral blood cells counts.
  
  
  CONCLUSIONS
  The data obtained demonstrated that GE132+Natural is effective in inhibiting cancer cell proliferation, indicating its potential beneficial health effects. In addition, the results pointed that adult mesenchymal stem cells might be valuable as a test system for evaluating the toxicity and efficacy of new medicines or chemicals.
authors.affiliation: Laboratory for Experimental Hematology and Stem Cells, Institute for Medical Research, University of Belgrade, Belgrade, Serbia.
authors.forename: I
authors.initials: I
authors.lastname: Okic-Djordjevic
authors.forename: D
authors.initials: D
authors.lastname: Trivanovic
authors.forename: J
authors.initials: J
authors.lastname: Krstic
authors.forename: A
authors.initials: A
authors.lastname: Jaukovic
authors.forename: S
authors.initials: S
authors.lastname: Mojsilovic
authors.forename: J F
authors.initials: JF
authors.lastname: Santibanez
authors.forename: M
authors.initials: M
authors.lastname: Terzic
authors.forename: D
authors.initials: D
authors.lastname: Vesovic
authors.forename: D
authors.initials: D
authors.lastname: Bugarski
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000633:toxicity; D001773:Blood Cells / Q000187:drug effects; D001943:Breast Neoplasms / Q000473:pathology*; D049109:Cell Proliferation / Q000187:drug effects*; D003110:Colonic Neoplasms / Q000473:pathology*; D019587:Dietary Supplements / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D042783:Endothelial Cells / Q000187:drug effects; D005260:Female; D006801:Humans; D061986:MCF-7 Cells; D008297:Male; D059630:Mesenchymal Stem Cells / Q000187:drug effects; D011471:Prostatic Neoplasms / Q000473:pathology*
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations